Alnylam Pharmaceuticals, Inc. $ALNY Stock Holdings Decreased by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA lessened its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 24.7% in the 1st quarter, Holdings Channel reports. The fund owned 237,920 shares of the biopharmaceutical company’s stock after selling 78,133 shares during the period. Pictet Asset Management Holding SA’s holdings in Alnylam Pharmaceuticals were worth $77,494,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ALNY. Sterling Capital Management LLC grew its position in Alnylam Pharmaceuticals by 45.7% during the 1st quarter. Sterling Capital Management LLC now owns 5,182 shares of the biopharmaceutical company’s stock worth $1,715,000 after purchasing an additional 1,625 shares in the last quarter. Cannon Global Investment Management LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the first quarter worth $794,000. Draper Asset Management LLC boosted its position in shares of Alnylam Pharmaceuticals by 55.8% in the first quarter. Draper Asset Management LLC now owns 3,773 shares of the biopharmaceutical company’s stock worth $1,248,000 after buying an additional 1,351 shares during the period. Louisiana State Employees Retirement System purchased a new position in shares of Alnylam Pharmaceuticals during the first quarter valued at $2,879,000. Finally, OP Asset Management Ltd purchased a new position in shares of Alnylam Pharmaceuticals during the first quarter valued at $7,768,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Up 0.7%

ALNY opened at $293.52 on Tuesday. The company has a market capitalization of $39.19 billion, a PE ratio of 80.20 and a beta of 0.29. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $273.11 and a fifty-two week high of $495.55. The business has a 50-day moving average of $295.73 and a 200-day moving average of $330.52.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, beating the consensus estimate of $0.87 by $1.12. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The business had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.12 billion. During the same quarter in the previous year, the business posted ($0.44) EPS. The firm’s quarterly revenue was up 96.4% compared to the same quarter last year. Equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post 7.47 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ALNY has been the subject of several research analyst reports. Chardan Capital reissued a “buy” rating and issued a $425.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 25th. Weiss Ratings raised Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Wells Fargo & Company upped their target price on Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the company an “equal weight” rating in a report on Friday, May 1st. Jefferies Financial Group reissued a “hold” rating and issued a $330.00 price target (down from $522.00) on shares of Alnylam Pharmaceuticals in a research report on Monday, March 16th. Finally, Wall Street Zen upgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $461.39.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, insider Melissa Mclaughlin sold 2,286 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $330.42, for a total value of $755,340.12. Following the completion of the sale, the insider directly owned 9,443 shares in the company, valued at $3,120,156.06. The trade was a 19.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director David E. I. Pyott sold 3,830 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the sale, the director directly owned 1,582 shares of the company’s stock, valued at $473,302.76. This represents a 70.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 7,740 shares of company stock valued at $2,420,214 over the last quarter. Corporate insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.